Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.73 |
| ▸ | HTR2C | P28335 | 19/20 | 0.73 |
| ▸ | HTR2B | P41595 | 19/20 | 0.73 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | LTK | P29376 | 1/20 | 0.36 |
| ▸ | GRK5 | P34947 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183789 | 0.85 | HTR2A (1.00) | HTR2AHTR2CHTR2B | |
| SCHEMBL183382 | 0.83 | HTR2A (0.80) | HTR2AHTR2CHTR2B | |
| SCHEMBL183515 | 0.79 | HTR2A (0.76) | HTR2AHTR2CHTR2B | |
| SCHEMBL183563 | 0.78 | HTR2A (0.74) | HTR2AHTR2CHTR2B | |
| SCHEMBL183557 | 0.78 | HTR2A (0.74) | HTR2AHTR2CHTR2B | |
| SCHEMBL183211 | 0.76 | HTR2A (0.67) | HTR2AHTR2CHTR2B | |
| SCHEMBL300985 | 0.74 | HTR2C (0.64) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL183667 | 0.74 | HTR2A (0.62) | HTR2AHTR2CHTR2B | |
| SCHEMBL183338 | 0.73 | HTR2C (0.78) | HTR2AHTR2CHTR2B | |
| SCHEMBL183573 | 0.71 | HTR2C (0.61) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618288-B2 | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-31 | — | — | US | claimed |
| EP-1928461-B1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-04 | — | — | EP | claimed |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-21 | — | — | US | claimed |
| EP-1928461-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-11 | — | — | EP | claimed |
| WO-2007019083-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | WO | claimed |
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | claimed |
| US-8618288-B2 | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-31 | — | — | US | disclosed |
| EP-1928461-B1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-04 | — | — | EP | disclosed |
| EP-1928461-B1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-04 | — | — | EP | disclosed |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-21 | — | — | US | disclosed |
| US-7598255-B2 | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-06 | — | — | US | disclosed |
| US-7598255-B2 | Pyrimidine compounds as serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-06 | — | — | US | disclosed |
| EP-1928461-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007019083-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019083-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032481-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR5A, HTR6 | HTR2A 4/4885HTR2C 11/4885HTR2B 10/4885 |
| US-20100016281-A1 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR5A, HTR6 | HTR2A 4/4885HTR2C 11/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.